Kobayashi Pharmaceutical Co (TSE:4967) Cyclically Adjusted Revenue per Share: 円0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4967 Kobayashi Pharmaceutical Co Ltd TSE:4967
81 GF Score
Price 円5,543.00
GF Value 円4,779.91
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Kobayashi Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Kobayashi Pharmaceutical Co TSE:4967 +0.76% 81 Cyclically Adjusted Revenue per Share is 円0.00 as of Jun. 2026. GuruFocus rates TSE:4967 with a GF Score™ of 81/100 and a GF Value™ of 円4,779.91 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kobayashi Pharmaceutical Co's adjusted revenue per share for the three months ended in Jun. 2026 was 円0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Kobayashi Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Kobayashi Pharmaceutical Co was 6.20% per year. The lowest was 1.90% per year. And the median was 4.10% per year.

As of today (2026-08-20), Kobayashi Pharmaceutical Co's current stock price is 円5543.00. Kobayashi Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was 円0.00. Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kobayashi Pharmaceutical Co was 7.06. The lowest was 2.27. And the median was 4.34.


Kobayashi Pharmaceutical Co  (TSE:4967) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kobayashi Pharmaceutical Co was 7.06. The lowest was 2.27. And the median was 4.34.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kobayashi Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Kobayashi Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Kobayashi Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kobayashi Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Kobayashi Pharmaceutical Co Annual Data
Trend Mar16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,850.37 1,977.12 2,091.42 2,215.68 2,295.20

Kobayashi Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,243.33 2,260.49 2,295.20 2,287.92 0.00

TSE:4967 vs PG, CL, KVUE: Cyclically Adjusted Revenue per Share Comparison

For the Household & Personal Products subindustry, Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kobayashi Pharmaceutical Co Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TSE:4967
81GF Score
Kobayashi Pharmaceutical Co Ltd TSE:4967
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kobayashi Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kobayashi Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/113.6000*113.6000
=0.000

Current CPI (Jun. 2026) = 113.6000.

Kobayashi Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 468.267 98.000 542.807
201612 570.578 98.400 658.716
201703 389.904 98.100 451.510
201706 464.388 98.500 535.578
201709 510.631 98.800 587.122
201712 621.337 99.400 710.099
201803 426.535 99.200 488.451
201806 492.766 99.200 564.297
201809 544.933 99.900 619.664
201812 653.932 99.700 745.102
201903 401.239 99.700 457.179
201906 480.293 99.800 546.706
201909 535.675 100.100 607.919
201912 603.073 100.500 681.683
202003 408.262 100.300 462.398
202006 438.430 99.900 498.555
202009 497.281 99.900 565.477
202012 581.669 99.300 665.434
202103 387.255 99.900 440.362
202106 470.594 99.500 537.281
202109 519.504 100.100 589.567
202112 610.093 100.100 692.373
202203 421.712 101.100 473.852
202206 499.715 101.800 557.639
202209 556.612 103.100 613.299
202212 679.295 104.100 741.286
202303 439.962 104.400 478.733
202306 527.506 105.200 569.626
202309 597.546 106.200 639.183
202312 723.983 106.800 770.079
202403 490.799 107.200 520.100
202406 493.025 108.200 517.631
202409 555.872 108.900 579.863
202412 687.601 110.700 705.614
202503 438.909 111.100 448.785
202506 489.803 111.700 498.134
202509 578.739 112.000 587.007
202512 722.430 113.000 726.266
202603 453.309 112.700 456.929
202606 0.000 113.600 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円0.00 mean?
Kobayashi Pharmaceutical Co (TSE:4967) has a Cyclically Adjusted Revenue per Share of 円0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kobayashi Pharmaceutical Co and its competitors.
Is Kobayashi Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Kobayashi Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円0.00. Overall, Kobayashi Pharmaceutical Co has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kobayashi Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to PG and CL?
Kobayashi Pharmaceutical Co's Cyclically Adjusted Revenue per Share of 円0.00 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kobayashi Pharmaceutical Co and its competitors. Kobayashi Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kobayashi Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kobayashi Pharmaceutical Co (TSE:4967) is currently considered Modestly Overvalued. The stock's GF Value™ is 円4,779.91, compared to a current price of 円5,543.00 — trading 16% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円0.00. Kobayashi Pharmaceutical Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Kobayashi Pharmaceutical Co (TSE:4967), the current Cyclically Adjusted Revenue per Share is 円0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kobayashi Pharmaceutical Co (TSE:4967) Overvalued in 2026?

Based on GuruFocus' analysis, Kobayashi Pharmaceutical Co stock appears to be overvalued. The current stock price of 円5,543.00 is trading 16% above its estimated GF Value™ of 円4,779.91. GuruFocus considers Kobayashi Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for TSE:4967:

  • Cyclically Adjusted Revenue per Share: 円0.00
  • GF Value™: 円4,779.91 vs. price of 円5,543.00 (16% above fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the TSE:4967 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kobayashi Pharmaceutical Co Business Description

Other Exchanges KOY:Germany
Address 4-4-10 Doshomachi, KDX Kobayashi Doshomachi Building, Chuo-ku, Osaka, JPN, 541-0045
Kobayashi Pharmaceutical Co Ltd is engaged in the manufacture and sale of healthcare products, daily necessities, and body warmers. The company operates through two reportable segments: Domestic Business and International Business, which handle production and sales activities in Japan and overseas, respectively. The company's product portfolio includes disposable body warmers, cooling gel sheets, OTC pharmaceuticals, oral hygiene products, air fresheners, eyeglass wipes, and deodorizing/household sundries.
81GF Score

Get the complete analysis for TSE:4967

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円5,543.00
Price
円4,779.91
GF Value